To recognize the value creators who have made outstanding contributions to China's healthcare industry over the past year and to establish an industry benchmark of 'respecting value, embracing value, and creating value', 2024year5month15day, byCHCMedical consultation, jointly launched with CITIC Securities,2023The 'Annual China Healthcare Industry Investment and Financing Honor Roll' was officially released.
The "Annual China Healthcare Industry Investment and Financing Honor Roll" is an authoritative third-party list in the healthcare sector. Based on a review of the current investment and financing development of the healthcare industry, it comprehensively evaluates institutions using multiple criteria such as activity level, number of investment projects, outstanding cases, return on investment, total managed capital, corporate financing and development status, valuation, etc. The list is produced following the principles of fairness and justice, including five categories: Investment Institutions, Enterprises, Services, Parks, and Individuals.15An award.
since2018Since the release of the first annual list, the Honor Roll has become one of the important benchmarks for the development and investment financing of China's healthcare industry. The release of the Honor Roll is not only an acknowledgment and affirmation of the value contributors in the healthcare industry but also an encouragement and motivation for the entire sector, reflecting the positive values and energy within the industry.
Frost & SullivanFrost & SullivanFrost & Sullivan', abbreviated as 'Frost & Sullivan'), with its excellent service quality, profound professional competence and sophisticated practice skills, escorts the development of clients. It provides efficient and high-quality professional services for the healthcare industry and has been honored as a '2023The Most Trusted Medical and Health Service Provider of the YearTop 5The list.
Frost & Sullivan integrates the globe63years of consulting experience,26Over the years, we have wholeheartedly served the booming Chinese market, using a global perspective to help clients accelerate their business growth, achieving benchmark positions in industry growth, innovation, and leadership. The Greater Health Industry is one of the core research areas of Frost & Sullivan.
Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, Frost & Sullivan has unique core advantages in investment and financing services for the life science industry. Frost & Sullivan has a wide range of corporate clients in China and in the past20In the year, a vast customer network was established, accumulating extensive project experience in various subfields of life sciences. Project types include Knowledge Center projects (in-depth content, promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising writing), market research, market value management and strategic consulting. We also cooperate with well-known domestic and international information platforms and investment and financing institutions, offering one-stop solutions in specialized fields such as pharmaceuticals and medical devices to enterprises. Our services have received wide attention from investors.
As an industry advisor, Frost & Sullivan has become the preferred partner for healthcare companies seeking to list in Hong Kong and overseas, thanks to its outstanding services. According to publicly disclosed information from the Hong Kong Exchange,2015till2023In FY, Frost & Sullivan went on to maintain its market-leading position in the Hong Kong-listed consultancy segment for the second consecutive year.9Maintaining a leading position year-on-year, we have been the absolute leader in assisting listed companies in the sub-market, serving as advisors for healthcare enterprises seeking listings in Hong Kong. In addition, since2019year7Since the first batch of companies on the Sci-tech Innovation Board of China were listed, Frost & Sullivan reports have also been widely cited in the prospectuses of leading Sci-tech Innovation Board-listed companies, accounting for as high as...75%.
since2018Since the beginning of this year, Frost & Sullivan has continuously released several industry blue books in the field of life sciences, such as 'Blue Book on the Current Development and Future Trends of Medical Beauty Injection Products', 'Blue Book on the Current Situation and Future Development Trends of High-End Ophthalmic Medical Equipment', 'Blue Book on the Development of Tumor Molecular Diagnosis Industry', 'Blue Book on the Current Situation and Development Trends of Vascular Interventional Special Balloons', 'Blue Book on the Current Situation and Future Development of China's Radioactive Drug Industry', 'Blue Book on the Current Situation and Development Trends of Gene Drug Industry',2023Hong Kong stocks for the year18A&Blue Book on the Development of Biotechnology Industry in the Sci-Tech Innovation Board Market, etc., deeply analyzes the current development status and future trends of various sub-industries, providing valuable reference perspectives for market investors.
In the future, Frost & Sullivan will continue to increase its investment and focus on the life sciences field, actively explore new service models and business models, pay attention to policy changes and market demands in the life sciences sector, and provide clients with more professional and efficient consulting services. We hope to work with more healthcare enterprises to understand industry trends, seize development opportunities, jointly promote the prosperity and development of China's healthcare industry, and contribute to the cause of human health.
